Additionally, in 2019, a Scandinavian-register-based cohort study compared the use of SGLT-2 inhibitors to the use of DPP4 inhibitors and showed a reduction in HF-associated and any-cause mortality as well as in cardiovascular events in patients treated with SGLT-2 inhibitors [145]. This evidence concerns the gene SLC5A2 and hydrops fetalis.